Technology in Cancer Research & Treatment最新文献

{"title":"miR-10b as a Clinical Marker and a Therapeutic Target for Metastatic Breast Cancer.","authors":"Alan Halim, Bryan Kim, Elizabeth Kenyon, Anna Moore","doi":"10.1177/15330338251339256","DOIUrl":"10.1177/15330338251339256","url":null,"abstract":"<p><p>Despite advances in cancer detection and treatment, metastatic breast cancer continues to carry a poor prognosis due to the lack of diagnostic and therapeutic resources that are specific to the metastatic process. MicroRNA-10b (miR-10b) is a small, noncoding RNA that is the focus of many studies due to its unique role as a driver of metastasis. The pathways it is involved in and the properties it confers have been reviewed previously and, collectively, are suggestive of the potential of miR-10b as a clinical marker and as a therapeutic target specific to metastatic disease. With the goal of application of our understanding of miR-10b to the clinic, in this mini-review, we highlight the studies that support the utility of miR-10b for these translational purposes.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251339256"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144111987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamics of VEGF-А, Аngiopoietin-2 and HIF-1α Levels in Patients with Brain Metastases Treated with Cyberknife Radiosurgery.","authors":"Veselin Popov, Gabriela Raycheva, Zhanet Grudeva-Popova","doi":"10.1177/15330338251313945","DOIUrl":"10.1177/15330338251313945","url":null,"abstract":"<p><p>The contemporary concept of carcinogenesis summarizes the role of hypoxia, neoangiogenesis, and hemostasis, including in the stage of progression and metastasis of the tumor process. Metastatic disease is a serious therapeutic challenge for any oncological condition. The purpose of this study was to evaluate the dynamics of specific indicators of neoangiogenesis and hypoxia as potential biomarkers for therapeutic efficacy or risk of disease progression in patients with brain metastases (BM) undergoing robotic stereotactic radiosurgery. Two groups of patients (lung cancer and other types of cancers) with oligometastatic disease and brain metastases were included. The patients (n = 66) were treated CyberKnife system. Human Angiopoietin-2, Hypoxia inducible factor 1 α (HIF-1α) and human Vascular Endothelial Growth Factor-А (VEGF-А) were measured in this prospective longitudinal study. Analysis of human Angiopoietin-2, HIF-1α, human VEGF-A in the post-treatment period showed a statistically significant decrease between the baseline and the 6 months post-treatment time point in both patient groups. The baseline value of serum VEGF-А in the group with lung cancer decreased by 40%, Аngiopoietin-2-by 48%, HIF-1α -by 43%. In the group with other types of cancers, VEGF-А decreased by 54.75%, Аngiopoietin-2-by 52%, HIF-1α -by 39.5%. Despite the significant reduction, the levels remained significantly higher in both groups than in healthy controls. This study underscores the potential of integrating molecular markers like VEGF-A, Angiopoietin-2, and HIF-1α into clinical decision-making to enhance outcomes for patients with brain metastases undergoing RSRS.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251313945"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptional Regulation of NUPR1 by MYH11 Activates PI3 K/AKT and Promotes Bladder Cancer Progression Through Ferroptosis and M2 Polarization of Macrophages.","authors":"Lifeng Zhang, Li Zhang, Zebin Shi, Yuanyuan Mi, Lei Zhang, Xiaokai Shi, Shenglin Gao, Li Zuo","doi":"10.1177/15330338241305434","DOIUrl":"10.1177/15330338241305434","url":null,"abstract":"<p><strong>Background: </strong>NUPR1 is a small molecule protein that plays an important role in tumor progression and drug resistance. Our previous study found that NUPR1 promotes the progression of bladder cancer, but the specific mechanism is still unclear. MYH11 encodes the smooth muscle myosin heavy chain and belongs to the conventional myosin family. MYH11 has been found to be associated with a variety of malignant tumors.</p><p><strong>Methods: </strong>We identified MYH11 as an upstream regulator of NUPR1 using a bioinformatics approach and tested this hypothesis by knocking down MYH11 and ChIP-qPCR. Subsequently, we verified the association of MYH11 and NUPR1 with the PI3 K/AKT pathway by WB. In addition, gene enrichment results showed that the effect of NUPR1 on bladder cancer was related to ferroptosis and M2 macrophage polarization. We examined ferroptosis metabolites in bladder cancer cells overexpressing NUPR1 and expression of the M2 macrophage marker CD206 in NUPR1 overexpression or MYH11 knockdown bladder cancer cells.</p><p><strong>Results: </strong>Bioinformatics results showed that MYH11 was positively correlated with NUPR1, and there may be a mutual binding site at the promoter of NUPR1. Knockdown of MYH11 decreased NUPR1 expression, and ChIP-qPCR showed that MYH11 bound to the promoter of NUPR1. Subsequently, WB results showed that MYH11 knockdown inhibited the PI3 K/AKT pathway, whereas NUPR1 overexpression activated this pathway. After adding ferroptosis activator, the viability of bladder cancer cells decreased, and the content of Fe²⁺ and MDA increased. However, ferroptosis was significantly inhibited after overexpression of NUPR1. Knockdown of MYH11 inhibited M2 macrophage polarization, while overexpression of NUPR1 promoted this process.</p><p><strong>Conclusion: </strong>This study suggests that MYH11 activates the PI3 K/AKT pathway by up-regulating the expression of NUPR1, and promotes bladder cancer progression by inhibiting ferroptosis and promoting M2 polarization of macrophages.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241305434"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carboxylesterase 4A Inhibits the Malignant Biological Behavior of Nasopharyngeal Carcinoma via the PI3K/AKT Pathway.","authors":"Qiaoli Chen, Quanxiang Hao, Yanping Yang, Limei Li, Danping Li, Ran Zhao, Wanqi Wei, Lixian Deng, Jiaming Su, Ziyuan Liang, Shiyue Tang, Yaomin Lu, Yushan Liang, Zhe Zhang, Xiaoying Zhou, Xue Xiao, Ping Li, Yi Huang, Weilin Zhao","doi":"10.1177/15330338251319144","DOIUrl":"10.1177/15330338251319144","url":null,"abstract":"<p><strong>Background: </strong>Carboxylesterase 4A (CES4A) belongs to the member of the carboxylesterase family, yet there has been limited research into its malignant biological behavior in malignant tumors. Here, we aim to investigate the expression, cellular biological functions, and the potential underlying mechanism of CES4A in nasopharyngeal carcinoma (NPC).</p><p><strong>Method: </strong>A standardized mean difference (SMD) analysis was used to analyze the dysregulation of CES4A based on the gene expression omnibus (GEO) database. qRT-PCR and immunohistochemical staining (IHC) were used to identify the mRNA and protein levels of CES4A in NPC cell lines and tissues, respectively. CCK-8, colony formation, wound healing and transwell assays were utilized to estimate cellular growth and metastasis, respectively. Western blot was conducted to evaluate the activity of PI3K/AKT signaling pathway.</p><p><strong>Result: </strong>Both mRNA and protein expression of CES4A was significantly diminished both in NPC cell lines and primary tumor tissues. Ectopic expression of CES4A restrains the proliferation, colony formation, migration and invasion of NPC. Additionally, KEGG analysis based on GEO data and high-throughput transcriptome sequencing of cell lines all strongly suggested that CES4A was involved in regulating phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway. It was observed that AKT and phosphorylated AKT were remarkably reduced in CES4A overexpressing NPC cells, indicating that PI3K/AKT signaling pathway is hindered by CES4A.</p><p><strong>Conclusion: </strong>CES4A expression is silenced in NPC, functioning as a tumor suppressor by negatively modulating the PI3K/AKT signaling pathway.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251319144"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11800256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143256550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>In Vitro</i> Potentiation of Doxorubicin Cytotoxicity Utilizing Clarithromycin Loaded-PEGylated Liposomes.","authors":"Islam Alfreahat, Hamdi Nsairat, Ibrahim Deeb Aldeeb, Ali Al-Samydai, Walhan Alshaer","doi":"10.1177/15330338241312561","DOIUrl":"10.1177/15330338241312561","url":null,"abstract":"<p><strong>Background: </strong>Doxorubicin (DOX) is a potent chemotherapeutic agent for breast cancer, but its effectiveness is often diminished by resistance mechanisms, particularly through p-glycoprotein (P-gp) mediated drug efflux. Clarithromycin (CAM), a macrolide antibiotic, inhibits multiple metabolic pathways including CYP3A and P-gp, potentially countering DOX resistance.</p><p><strong>Objective: </strong>This study aimed to evaluate the potentiation of DOX and its effectiveness against the MCF-7 breast cancer cell line by encapsulating both DOX and CAM in PEGylated liposomes.</p><p><strong>Methods: </strong>PEGylated liposomes containing DOX and CAM were prepared using the thin film hydration method. The physicochemical properties of the liposomes, including average particle size, polydispersity index (PDI), and zeta potential, were characterized. Encapsulation efficiencies for CAM and DOX were assessed, and stability of the liposomes was evaluated over 9 days at room temperature. Cell viability was measured using an IC₅₀ assay, and P-gp expression levels were determined by ELISA.</p><p><strong>Results: </strong>The CAM/DOX-PEGylated liposomes exhibited optimal average particle size (238 ± 26.7 nm), PDI (0.29 ± 0.107), and zeta potential (-20.9 ± 2.17 mV). These liposomes maintained good stability regarding size and charge over 9 days. Encapsulation efficiencies were 81.05% for CAM and 78.13% for DOX. The IC50 value for CAM/DOX-PEGylated liposomes was 0.13 µM, representing a significant reduction compared to the physical mixture of CAM and DOX (0.25 µM) and free DOX (0.21 µM) against MCF-7 cells. ELISA analysis showed a reduction in P-gp expression of approximately 5% with CAM/DOX-PEGylated liposomes compared to 1.61% with free DOX.</p><p><strong>Conclusion: </strong>The results indicate that CAM encapsulated in PEGylated liposomes enhances the effectiveness of DOX against breast cancer cells, likely through the inhibition of p-glycoprotein. This approach may offer a promising strategy to overcome DOX resistance and improve chemotherapy outcomes.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241312561"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spot-Scanning Confocal Photon Beams for Hypofractionated Brain Radiosurgery.","authors":"Lijun Ma, Shuang Luan, Nguyen Phuong Dang, Benjamin Ziemer, Steve Braunstein, Michael McDermott, Cheng Yu, Gabriel Zada, Eric L Chang","doi":"10.1177/15330338251342873","DOIUrl":"10.1177/15330338251342873","url":null,"abstract":"<p><p>IntroductionStereotactic radiosurgery (SRS) has been broadly used to treat brain tumors. In this study, a dose kernel-based spot scanning (DKSC) treatment delivery has been developed for hypofractionated brain SRS.MethodsDKSC treatments employs hundreds of confocal photon dose kernels. For such a delivery, a single continuous scanning path was first mapped within a 3D target volume, and then a series of dose kernels of variable sizes, shapes and beam weights were placed and then optimized along the path to produce highly conformal dose distributions. For implementation of DKSC delivery in a clinical setting, we specifically employed the Leksell Gamma Knife (LGK) system, where it is considered as the gold standard of modern SRS treatments.ResultsDKSC was successfully implemented for a patient treatment for the first time. General methodology as well as specific workflow and treatment planning caveats of implementing DKSC for the LGK is reported. To highlight the novelty of DKSC, we also compared DKSC against the conventional LGK-SRS treatment including its latest treatment planning optimization software.ConclusionDKSC has been demonstrated to be technically feasible, clinically implementable, and uniquely advantageous for hypofractionated brain SRS. Further studies are warranted toward testing DKSC for variable SRS modalities, different disease sites including extra-cranial lesions.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251342873"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting Mesothelioma Using Artificial Intelligence: A Scoping Review of Common Models and Applications.","authors":"Malihe Ram, Mohammad Reza Afrash, Khadijeh Moulaei, Erfan Esmaeeli, Mohadeseh Sadat Khorashadizadeh, Ali Garavand, Parastoo Amiri, Azam Sabahi","doi":"10.1177/15330338251341053","DOIUrl":"10.1177/15330338251341053","url":null,"abstract":"<p><p>IntroductionMesothelioma is a type of lung cancer caused by asbestos exposure, and early diagnosis is crucial for improving survival chances. Artificial intelligence offers a potential solution for the timely diagnosis and staging of the disease. This study aims to review the latest research conducted in artificial intelligence applications to predict mesothelioma.MethodsUntil April 24, 2023, PubMed, Scopus, and Web of Science databases were searched comprehensively for articles on artificial intelligence in mesothelioma management. The data was gathered using a standardized extraction form, and the findings were reported in figures and tables.ResultsOne hundred and seventy-three articles were identified from database searches, which were then reduced to 151 after eliminating duplicates. Finally, 19 articles were selected for inclusion in our study. The applications of artificial intelligence in these articles primarily focused on tumor diagnosis and classification (73.69%), followed by prevention and prognosis (21.05%) and tumor volumetric measurement of malignant pleural mesothelioma (5.26%). The most frequently used AI models include types of neural networks (NN), decision trees (DT), random forests (RF), logistic regression (LogR), Naïve Bayes (NB), and support vector machines (SVM). SVM, DT, and RF emerged as prominent models, achieving high accuracies ranging from 78.3% to 99.97%. Genetic algorithms, correlation-based algorithms, and Neural Networks were employed for risk factor identification and feature selection.ConclusionArtificial intelligence, particularly machine learning models such as neural networks, decision trees, support vector machines, and random forests, holds promise in predicting and managing mesothelioma, potentially enhancing early detection and improving patient outcomes.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251341053"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12065984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiobiological Modeling with Monte Carlo Tools - Simulating Cellular Responses to Ionizing Radiation.","authors":"Tiago André Azevedo, Ana Margarida Abrantes, João Carvalho","doi":"10.1177/15330338251350909","DOIUrl":"10.1177/15330338251350909","url":null,"abstract":"<p><p>As the prevalence of cancer continues to rise in a rapidly aging population, the integration of advancements in computational capabilities with oncological practices presents promising opportunities for enhancing cancer treatment management. <i>In silico</i> modeling has emerged as a key approach for studying the radiobiological aspects of cancer, providing novel pathways for understanding cellular mechanisms and potential future improvements in clinical radiotherapy. This review examines significant advancements and ongoing challenges in simulating the complex interactions of ionizing radiation with cancer cells. We explore the utility and limitations of current <i>in silico</i> models, including agent-based models and hybrid approaches that integrate cellular behavior with radiobiological effects using Monte Carlo tools. The paper highlights key developments that have enabled more accurate simulations of DNA damage, various repair processes, and the influence of the microenvironment on cellular radiosensitivity. Looking ahead, we address the need for further refinement of these models and their integration with experimental data to enhance predictive accuracy and potential clinical applications. The capacity of these models to potentiate personalized cancer therapy is emphasized, highlighting the ongoing shift towards more comprehensive and sophisticated computational approaches.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251350909"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12276521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144650544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver Transplantation for Unresectable Colorectal Liver Metastases.","authors":"Yash Kadakia, Omar Bushara, Maarouf Hoteit, Peter Abt","doi":"10.1177/15330338251361238","DOIUrl":"10.1177/15330338251361238","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is the third most common malignancy worldwide and a leading cause of cancer-related death. Nearly half of CRC patients develop metastatic disease, with the liver being the most frequent site of metastases. While curative-intent surgical resection remains the gold standard for colorectal liver metastases (CRLM), most patients are initially ineligible for surgery, and recurrence rates remain high. Systemic chemotherapy is the primary treatment for unresectable CRLM, with some patients achieving downstaging to surgical eligibility. Alternative approaches, including immune checkpoint inhibitors for MSI-H/dMMR cancers, hepatic artery infusion pumps, and locoregional therapies, have been explored to improve survival. Liver transplantation (LT) was initially abandoned for CRLM due to poor outcomes, but advancements in surgical techniques, immunosuppression, and donor availability have reignited interest in this approach. With LT becoming an established option for hepatocellular carcinoma and cholangiocarcinoma, its potential role in treating unresectable CRLM is being reconsidered. This review provides the latest evidence on LT for CRLM, including patient selection, outcomes, and future research directions.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251361238"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12276470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bolus Use in Postmastectomy Radiation Therapy for Breast Cancer: A Systematic Literature Review.","authors":"Fengyan Li, Wendie Hu, Hanzong Li, Bohan Li, Yaxue Wang","doi":"10.1177/15330338251344521","DOIUrl":"10.1177/15330338251344521","url":null,"abstract":"<p><p>IntroductionTissue-equivalent boluses are used to increase the skin surface dose in patients with breast cancer undergoing postmastectomy radiotherapy. Boluses made from various materials have been developed and applied in clinical practice. However, there is currently no international standardization for their use. This study aimed to analyze the advantages and disadvantages of using compensatory membranes (boluses), identify the optimal patient population for their postoperative application, and determine the most suitable types of compensatory membranes for use in postoperative radiotherapy for breast cancer.MethodsThis study includes a systematic literature review of sources such as websites, books, and articles from January 2013 to December 2023. We analyzed and compared studies on the use of compensatory membranes in postoperative radiotherapy for breast cancer, evaluating differences among various bolus materials as well as the impact of using no bolus. Outcomes such as patient responses and prognosis were also assessed. After excluding abstracts, reviews, and other non-research articles, a total of 32 studies were included in the analysis.Results3D-printed boluses and brass mesh boluses show promise as alternatives to traditional bolus materials, with potential for broader clinical application. The use of a bolus can increase the incidence of acute radiation-induced toxicities, without significant improvements in long-term patient prognosis. For patients receiving chest wall radiotherapy after breast cancer surgery, bolus use may be considered selectively, especially in those with high-risk factors.ConclusionCurrently, there is no unified standard for bolus use in breast cancer patients undergoing chest wall radiotherapy following modified radical mastectomy. This review provides a critical evaluation of existing literature, summarizing the available bolus materials and their influence on radiotherapy outcomes in postoperative breast cancer treatment.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251344521"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}